The BioButton Rechargeable Device Joins BioIntelliSense’s Growing Portfolio of
Award-Winning Remote Care Technologies Enabling Medical Grade Continuous
Care from In-Hospital to the Home
BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company,
expands its commitment to creating a new standard of remote patient care with the commercial launch of its medical
grade BioButton® Rechargeable wearable device. The new BioButton Rechargeable device allows for continuous
multi-parameter monitoring of a broad range of 20+ vital signs and physiologic biometrics for up to 30 days on a
single charge. The device’s comprehensive set of leading indicators allows for the early identification and detection
of adverse trends to improve patient monitoring safety and efficacy from in the hospital to the home. This newest
addition to BioIntelliSense’s leading portfolio of medical grade wearable devices and data services provides a
simplified and cost-effective continuous monitoring solution for managing patient populations with chronic, complex
care needs month-over-month or for even years.
About BioIntelliSense
BioIntelliSense is ushering in a new era of continuous health monitoring and
clinical intelligence for Remote Patient Monitoring (RPM). Its medical-grade Dataas-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs,
physiological biometrics and symptomatic events through an effortless patient
experience. The FDA-cleared BioSticker™ and medical-grade BioButton® devices
make remote monitoring and early detection simple. Through the platform’s
advanced analytics, clinicians will now have access to high-resolution patient
trending and reporting to enable medical grade care at home.
Learn how BioIntelliSense is redefining remote patient monitoring through
medical-grade and cost-effective data services or visit our website at
BioIntelliSense.com.
The BioButton Rechargeable device offers a comprehensive range of 20+ patient trending and algorithmic-based
personalized alerts including temperature, resting heart rate, respiratory rate, body position, activity levels, gait
analysis, infection-like symptoms and more. The BioIntelliSense continuous monitoring solutions are being rapidly
adopted and deployed in the U.S. and select international markets for medical-grade monitoring across care
settings namely in-patient status monitoring, hospital at home, ED observation, post-discharge complex care
management and remote monitoring at home. Learn more about how BioIntelliSense is making early detection
simple™ at the HIMSS Global Health Conference & Exhibition March 14-18, 2022 in Orlando, Florida.
Follow BioIntelliSense on Twitter and LinkedIn for the latest news and information
